Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male and female participants who are classically healthy having no clinically relevant abnormalities. No known or suspected hepatic impairment
Stable hepatic impairment that meets the criteria for Class B of the Child-Pugh Classification
You may not be if
Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection).
Participants who have been vaccinated with COVID-19 vaccines within the past week of dosing
A positive urine drug test, for illicit drugs, at Screening
History of sensitivity reactions to ritonavir or any of the formulation components of PF-07321332 or ritonavir.
eGFR \<60 mL/min/1.73m2 based on the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥ upper limit of normal (ULN) (for healthy participants); AST or ALT \> 5x ULN (for hepatic impairment participants)
Albumin \> ULN (for healthy participants);
Prothrombin time \> ULN (for healthy participants);
Total bilirubin level ≥1.5 × ULN \[NOTE: Participants with a history of Gilbert syndrome (and hence elevated total bilirubin) are eligible provided direct bilirubin level is ≤ ULN).
Clareo Health | Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
